基石藥業(02616.HK)擬於10月中旬ESMO大會發表CS2009及CS5001研究數據
基石藥業-B(02616.HK)宣布,將於2025年10月17日至21日舉行的歐洲腫瘤內科學會(ESMO)年會上,首次公布PD1/VEGF/CTLA-4三特異性抗體CS2009的Ia期臨床研究數據,以及ROR1抗體藥物偶聯物(ADC)CS5001的全球Ib期研究設計。
目前CS5001的全球多中心Ib期臨床試驗正在美國、澳洲和中國同步推進,而CS2009的全球多中心I期劑量遞增和劑量擴展研究正在澳洲和中國積極招募患者,並計劃擴展至美國進行II期入組。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.